Defence Therapeutics Inc. (OTCMKTS:DTCFF) (CSE:DTC) Stock Falls 10% In a Week: here is Why
Defence Therapeutics Inc. (OTCMKTS:DTCFF) (CSE:DTC) is down 10% in a week. The company has announced the creation of AccuVAC-PT009, which is a novel HPV vaccine that is protein-based, resulting in a humoral response circumventing Gardasil-9 immunogenicity in animals.
Market Stats
On Wednesday, DTCFF stock ended flat at $3.94 with more than 8 shares, compared to its average volume of 1.2K shares. The stock has moved within a range of $3.9400 – 3.9400 after opening trading at $3.94.
Defence’s Accum(TM)-HPV Vaccine Formulation (AccuVAC-PT009) Activates a 36-Fold Higher Humoral Response Compared to Gardasil-9
In addition, the company owns 100% of the ACCUM technology platform. This game-changing innovation can be utilized to improve the intracellular aggregation of pharmacologically relevant proteins in any target cell. As a result, the company is presently using it to produce many COVID and anti-cancer vaccines and to improve antibody-drug conjugates that are either authorized or in development.
Therefore, to show how versatile ACCUM is, its R&D team created an HPV vaccine (a combination of identical 9 HPV-sourced L1 proteins utilized in Gardasil-9) and tested its immunogenicity against a sample Gardasil-9-immunized animal subjects. AccuVAC-PT009 produces a 27- and 36-fold rise in antibody titer increase at four and six weeks after immunization, respectively, in comparison to Gardasil-9. So, DTCFF is worth watching in the coming weeks.
Key Quote
“We are extremely proud to demonstrate again how ACCUMTM can be exploited and applied to significantly improve any protein-based vaccine. Not only can this vaccine have a tremendous impact on improving the immunogenicity of the commercialized Gardasil-9, but it can in addition lower the dosing regimen (at least by 10-fold) yet triggering similar or more potent humoral response”, says Mr. Plouffe, the CEO of Defence.
